Neogenomics (NEO) Issues Q2 Earnings Guidance

Share on StockTwits

Neogenomics (NYSE:NEO) updated its second quarter earnings guidance on Wednesday. The company provided EPS guidance of $0.00-0.01 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.00, AnalystRatings.NET reports. The company issued revenue guidance of $18.8-19.3 million, compared to the consensus revenue estimate of $17.27 million.

On a related note, analysts at Stephens initiated coverage on shares of Neogenomics in a research note on Friday, February 14th. They set an overweight rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $6.50.

Neogenomics (NYSE:NEO) opened at 3.48 on Wednesday. Neogenomics has a 52 week low of $2.05 and a 52 week high of $4.69. The stock’s 50-day moving average is $3.43 and its 200-day moving average is $3.59. The company has a market cap of $170.9 million and a price-to-earnings ratio of 86.25.

Neogenomics (NYSE:NEO) last released its earnings data on Wednesday, February 19th. The company reported $0.04 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.02 by $0.02. The company had revenue of $18.30 million for the quarter, compared to the consensus estimate of $17.80 million. On average, analysts predict that Neogenomics will post $0.01 earnings per share for the current fiscal year.

NeoGenomics, Inc (NYSE:NEO) operates a network of cancer-focused testing laboratories.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Acme United Corp.  Set to Announce Earnings on Thursday
Acme United Corp. Set to Announce Earnings on Thursday
Altera  to Release Earnings on Thursday
Altera to Release Earnings on Thursday
Barclays Increases Prologis Price Target to $45.00
Barclays Increases Prologis Price Target to $45.00
Zacks Reiterates “Outperform” Rating for Allergan
Zacks Reiterates “Outperform” Rating for Allergan
JMP Group Stock Rating Upgraded by FBR Capital Markets
JMP Group Stock Rating Upgraded by FBR Capital Markets
Jefferies Group Increases Simon Property Group Price Target to $193.00
Jefferies Group Increases Simon Property Group Price Target to $193.00


Leave a Reply

 
© 2006-2014 Mideast Time.